THCB

Categories

Above the Fold

Finding a Faster Route From Patent to Patient

• 4

By Wendy Everett

Wendy_everettAs the health reform debate intensifies, the rightful role of medical technologies is stuck squarely in the
middle, caught in a simplistic tug-of-war over whether these innovations raise or lower health care costs. Instead of this argument, we should be focused on how to best identify the truly valuable technologies – those with potential to save both lives and money – and get them into the health care marketplace.

So how can we ensure that the U.S. is making smart investments in innovative technologies that pay dividends for patients and the system, something Europe, Canada and many other countries are already doing?

Answering this question would give us a shot at fixing some of the most broken parts of health care. Technologies can play a key role in the redesign of the ailing primary care system by providing quality patient data, assisting in preventive practices, and taking the burden off the backs of primary care physicians. Similarly, technologies can help combat and manage the massive burden of chronic disease, and they can help reduce the costly clinical waste and inefficiency plaguing the system.

Continue reading…

Making Price Competition Work

• 12

By ROGER COLLIER

Wall Street Journal editorial writers and other folk with touching faith in classic economic theory wonder from time to time why competition doesn’t work better in the health care system. (Actually, the WSJ people are sure that it could, if it were not for government bureaucrats and their spendthrift liberal friends).

It does seem as if Adam Smith’s “invisible hand” is affected by a strange palsy as it nears the realm of health care. But why, given the legions of insurers and providers all apparently eager to edge each other out in the race for our dollars?

Continue reading…

Economic Forces Reshaping Medicare Drug Benefit

• 1

By Bonnie Washington

WashingtonB_820After years of relative consumer inertia in the Medicare drug  benefit plan selection process, the economy
created the first real test of Medicare drug plans' stickiness.  Would seniors stay loyal  to their last drug plan choice, or would they be more willing to shop around to chase savings?

New data released today by Avalere Health shows that 1 of every 3,  or more than 9 million, Medicare beneficiaries has picked a Medicare  Advantage plan with prescription drug coverage (MA-PD plans) as their way to access medications.  Growth in MA-PDs far outpaced enrollment in standalone drug plan, or PDPs, for 2009.  MA-PDs; picked up about 730,000 people relative to mid-2008 levels, while  total enrollment in standalone prescription drug plans, or PDPs, increased by about 140,000 individuals over the same period.

How to explain MA-PDs newfound popularity?  It's the economy, of course.  

Continue reading…

Open Source Health Research

• 3

By Matthew Holt

CureTogetherI'm doing a first for THCB which is a IM chat interview. On the other side of the keyboard (so to speak) is Alexandra Carmichael who is the CEO of CureTogether.com. Hi Alex!

Alexandra: Hi Matthew, nice to IM with you!

Me: So we're trying this out and we'll talk about Repetitive Stress Injuries later!!

Now CureTogether was a late add to a panel at Health 2.0 last October, but to be fair you are very early in the process of what you're calling Open Source Health Research. Before you tell us what that is, can you tell me a bit about your background.

Alexandra: Sure, you can add Repetitive Strain as a condition on CureTogether.

I started out in molecular genetics, actually, at the University of Toronto, Canada. I left grad school to co-found Redasoft, a molecular biology software company, with Daniel Reda. We grew the company over 10 years to having customers in 37 countries, then sold the technology we developed to Hitachi Software in 2005. We moved to California, consulted with Hitachi for a couple of years, and then were ready to dive into a new project.

Continue reading…

Commentology

• 0

Joe Flower had this to say in response to criticism of comparative effectiveness research in the comment thread on his post ("Fear and Loathing Over the Stimulus Bill") examining the backlash against the Health IT provisions in the stimulus package …

"No one that I can see is saying that doctors and patients should not
be allowed to choose the best treatment. But there need to be some
bounds, some incentives to pay attention to what the best evidence
shows. Why don't doctors do bloodletting, as they routinely did 200
years ago? Why don't they whip out every kid's tonsils, as they did
when I was a kid? What happened to the idea that radical mastectomy was
the gold standard treatment for breast cancer? What about the fad for
high-dose chemo and bone marrow transplants for breast cancer, all
before studies showed little benefit and great risk? What about all the
routine things that are still done that have shown little benefit in
studies (like routine episiotomies, brain bypass surgery for patients
with warning signs of stroke, or HRT to prevent a second heart attack
in women)? What about the hundreds of thousands of spinal fusions still
being done, not for tumors or spinal fractures or congenital problems,
for which the surgery shows great benefit, but for chronic back pain,
for which repeated studies show little long-term advantage over
non-surgical techniques?

What do we do with such information? Do we just shrug our shoulders
and do nothing about it? Do we wonder whether such over-treatment with
unproven or even disproven therapies has anything to do with the fact
that we spend roughly twice as much per capita as every other major,
medically modern economy, whether socialized or mixed, for worse
outcomes, and still can't seem to afford to offer even basic care to
all Americans?"

Raising the Price Before You Put It On Sale

• 3

By ROBERT LASZEWSKI

 The Obama budget team has made it clear they are going into the next federal budget process playing it straight on many fronts that the prior administration had fudged on. The
cost of the wars, the cost of adjusting the alternative minimum tax
each year to keep the middle class from falling into it, the cost of
disaster relief, and the cost of avoiding the otherwise automatic cuts
to Medicare physician fees because of the Sustainable Growth Rate (SGR) formula were all conveniently left out of the Bush budgets making them look a lot better than they really were.

Facing a $1.5 to $2 trillion deficit this year
you might as well throw the lot on the pile, get it over with, and
create an even greater imperative for change—a trillion here a trillion
there "and pretty soon it gets to look like real money."

In the end an honest accounting is all to the Obama administration’s credit.

But on the health care front anyway, it may also be very shrewd politics.

Continue reading…

Betsy McCraker misses the point, again

• 0

By Matthew Holt

Not content with being the catalyst for the unleashing of a torrent of vitriol in the direction of those Milquetoast individuals who are in favor of better information systems in health care, in the mild expectation that it might improve care delivery, Betsy McCracker is back at it again. This time the NY Times prints her letter. And in it she says:

These changes will affect all of us, at the least by requiring that our treatments be recorded in a federally mandated electronic database and guiding the choices our doctors make. Yet no hearings were held, no expert witnesses called, no opinions gathered from patient advocates, doctors’ groups, the elderly or other stakeholders.

Apart from the fact that there’s no evidence of one “electronic database”, she’s missed a couple of things.

First, hearings, witnesses, etc, etc, have been held for on this topic for years, and witnesses were called in the weeks before the stimulus bill—Microsoft’s Peter Neupert among them. Peter may not be an expert in Betsy’s eyes, but I think most of us would concede that he knows something about the topic (even though much of his advice was ignored).

Secondly, Betsy McCracker seems to be missing a minor point. The Obama campaign was not shy about telling anyone who listened that they were going to spend up to $50 billion on health IT in the next five years. It was on their website, and talked about by their health care advisers non-stop, as the WaPo noticed in early December.

Why are we supposed to be surprised that they did what they said they were going to do? Isn’t that the point of democracy? So Betsy, who won the election?

Yelp: The Backlash Begins…

• 4

By Matthew Holt

Picture 25There's a pretty serious article about Yelp, which has become the dominant player in restaurant and 
service reviews in the SF Bay Area, in a local alternative weekly The East Bay Express called Yelp and the Business of Extortion 2.0.

Now recently Yelp has seen a couple of its reviewers sued for reviews about health care providers (both chiropractors), and the issue about what reviewers can say online is probably still to be worked out.

But this article is about something much worse. It accuses Yelp of changing reviews, eliminating them, and generally breaching the church/state line between community and sponsorship.

And it goes both ways. Businesses that advertise get bad reviews “disappeared” and those who don’t find their good reviews are vanishing.

Continue reading…

Disruption breaking out over at Scott Shreeve’s place

• 2

Clayton Christensen's publisher is pressing me to read The Innovators Prescription and then interview him. Sadly I haven’t had the time to pay the book the attention it deserves. Messrs Kuraitis & Kibbe already did a review on THCB and probably said what I’d say, which was that like several other Harvard Business School profs, they got the problem right but the solution wrong. I’m on record from a couple of years back saying that Christensen’s guns are aimed in the wrong direction.

But to be fair my criticisms are pre-publication. Scott Shreeve has a great interview with Christensen’s co-author Jason Hwang (the late Jerome Grossman is also a co-author). and in this interview several of the incentive issues which concern those of us who understand how innovation gets stopped in health care, are addressed. Well worth reading.

Continue reading…

A Randomized Trial of Niceness in the ER and Other Stories

• 7

By BOB WACHTERBob Wachter

One of the great joys of a life in academic medicine is the opportunity to work with lots of very smart people. But one regret is that there is something about academia that tends to homogenize – faculty learn that, when it comes to competing for the next grant or promotion, it pays to be clever but relatively conventional. Sure, innovation is the coin of the realm, but out-of-the-box, quirky thinkers generally need not apply.

With one exception. I’d like to introduce you to the mind of Don Redelmeier, Professor of Medicine at the University of Toronto, and, to me, the most creative researcher in healthcare, perhaps all of science, today.

I came to know Don when we were both Robert Wood Johnson Clinical Scholars at Stanford University in the late 1980s, and we became fast friends. His eccentricities were obvious even then. Take, for example, Don’s algorithm for analyzing his dates, using a complex formula that assigned point values for intelligence, looks, humor, and tennis playing ability (bonus points). It wasn’t very romantic, but it was hilarious (we all looked forward to Monday recaps of the weekend’s events) and generally accurate. Continue reading…